Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2018 Earnings Results

Rhythm Pharmaceuticals Misses on EPS, Stock Up 12.83%

Rhythm Pharmaceuticals reported a loss per share of $0.60, which was in line with expectations as no consensus was available. Despite the loss, the stock rose by 12.83%, likely driven by positive sentiment around their product pipeline and management's commitment to growth. Investors may be optimistic about future developments even in the absence of revenue data.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.60	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their product pipeline. They acknowledged challenges but emphasized their commitment to future growth.

Management highlighted ongoing commitment to pipeline development.

They expressed confidence in long-term growth despite current challenges.

Rhythm Pharmaceuticals Misses on EPS, Stock Up 12.83%

Key numbers

Management commentary

Rhythm Pharmaceuticals, Inc.

More earnings this week

Rhythm Pharmaceuticals Misses on EPS, Stock Up 12.83%

Key numbers

Management commentary